SCHEMBL6157027

SCHEMBL6157027

CS(=O)(=O)OC1CC(=O)N(Cc2ccc(Oc3ccc(C(N)=O)cc3)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.40
PARP10 Q53GL7 2/20 0.40
PARP15 Q460N3 1/20 0.40
PARP14 Q460N5 1/20 0.40
PARP16 Q8N5Y8 1/20 0.40
PARP11 Q9NR21 1/20 0.40
PARP4 Q9UKK3 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
CCR5 P51681 1/20 0.38
OPRK1 P41145 3/20 0.38
OPRM1 P35372 2/20 0.38
OPRD1 P41143 1/20 0.38
MAPK1 P28482 1/20 0.38
ALOX15 P16050 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158314 0.87 CYP3A4 (0.41) ALDH1A1KMT2ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL6160102 0.85 CYP3A4 (0.48) ALDH1A1KMT2ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL6162338 0.85 KMT2A (0.47) ALDH1A1KMT2ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL6161999 0.85 SMN1; SMN2 (0.49) ALDH1A1KMT2ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL6158905 0.85 HPGD (0.44) CYP3A4CYP2C19SMN1; SMN2
SCHEMBL6160206 0.85 HPGD (0.44) CYP3A4CYP2C19SMN1; SMN2
SCHEMBL6166461 0.84 HTT (0.48) ALDH1A1KMT2ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL6158804 0.83 TDP1 (0.47) ALDH1A1KMT2ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL6157877 0.81 SMN1; SMN2 (0.44) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL6158864 0.80 PARP10 (0.46) ALDH1A1KMT2APARP10PARP15PARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 ALDH1A1 905/4885KMT2A 1898/4885PARP10 2828/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 ALDH1A1 877/4885KMT2A 1850/4885PARP10 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.